In what has been a very active week for the US regulator in terms of approving new biosimilar medicines, the US Food and Drug Administration has approved a copy version of the leukemia drug sold by Roche (ROG: SIX) subsidiary Genentech as Rituxan (rituximab).
Pfizer (NYSE: PFE) late Tuesday announced the FDA has approved Ruxience (rituximab-pvvr) for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
Roche’s MabThera/Rituximab (rituximab) generated first-quarter 2019 global sales 1.67 billion Swiss francs ($1.7 billion), down 1.3% year-on-year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze